These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 2188202)

  • 1. Metabolic and hematologic effects and immune complex formation related to pertussis immunization.
    Mink CM; Uhari M; Blumberg DA; Knip M; Lewis K; Christenson PD; Toyoda M; Jordan SC; Levin SR; Cherry JD
    Pediatr Res; 1990 Apr; 27(4 Pt 1):353-7. PubMed ID: 2188202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severe reactions associated with diphtheria-tetanus-pertussis vaccine: detailed study of children with seizures, hypotonic-hyporesponsive episodes, high fevers, and persistent crying.
    Blumberg DA; Lewis K; Mink CM; Christenson PD; Chatfield P; Cherry JD
    Pediatrics; 1993 Jun; 91(6):1158-65. PubMed ID: 8502521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-response to a two-component acellular pertussis vaccine in infants and comparison with whole-cell vaccine.
    Auerbach BS; Lake AM; Wilson ME; Willingham FF; Shematek J; Moulton L; Deforest A; Halsey NA
    Biologicals; 1998 Jun; 26(2):145-53. PubMed ID: 9811522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An open study evaluating the reactogenicity and immunogenicity of a DTP vaccine containing an acellular pertussis component in four to six year old children.
    Lewis K; Cherry JD; Baraff LJ; Robinson RG; Dudenhoeffer FE; Holroyd HJ; Baker LR; Farchione SL; Gurwith M; Vernon S
    Dev Biol Stand; 1985; 61():563-9. PubMed ID: 2872132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.
    Bisgard KM; Rhodes P; Connelly BL; Bi D; Hahn C; Patrick S; Glodé MP; Ehresmann KR;
    Pediatrics; 2005 Aug; 116(2):e285-94. PubMed ID: 16061582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results with a new DTP vaccine in Japan.
    Kimura M; Hikino N
    Dev Biol Stand; 1985; 61():545-61. PubMed ID: 2872131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of maternal antibody on the serologic response and the incidence of adverse reactions after primary immunization with acellular and whole-cell pertussis vaccines combined with diphtheria and tetanus toxoids.
    Englund JA; Anderson EL; Reed GF; Decker MD; Edwards KM; Pichichero ME; Steinhoff MC; Rennels MB; Deforest A; Meade BD
    Pediatrics; 1995 Sep; 96(3 Pt 2):580-4. PubMed ID: 7659480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minor adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group.
    Schmitt-Grohé S; Stehr K; Cherry JD; Heininger U; Uberall MA; Laussucq S; Eckhardt T
    Dev Biol Stand; 1997; 89():113-8. PubMed ID: 9272341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of a three-component acellular pertussis vaccine with a whole-cell pertussis vaccine in 15- through 20-month-old infants.
    Bernstein HH; Rothstein EP; Reisinger KS; Blatter MM; Arbeter AM; Fontana ME; Jacobs JM; Long SS; Rathfon H; Crayne O
    Pediatrics; 1994 Apr; 93(4):656-9. PubMed ID: 8134224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group.
    Uberall MA; Stehr K; Cherry JD; Heininger U; Schmitt-Grohé S; Laussucq S; Eckhardt T
    Dev Biol Stand; 1997; 89():83-9. PubMed ID: 9272335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group.
    Greco D; Salmaso S; Mastrantonio P; Giuliano M; Tozzi AE; Anemona A; Ciofi degli Atti ML; Giammanco A; Panei P; Blackwelder WC; Klein DL; Wassilak SG
    N Engl J Med; 1996 Feb; 334(6):341-8. PubMed ID: 8538704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneous administration of Haemophilus influenzae type b vaccine with acellular or whole-cell pertussis vaccine: effects on reactogenicity and immune responses to pertussis vaccines.
    Rennels MB; Reed GF; Decker MD; Edwards KM; Pichichero ME; Deloria MA; Englund JA; Anderson EL; Steinhoff MC; Deforest A
    Pediatrics; 1995 Sep; 96(3 Pt 2):576-9. PubMed ID: 7659479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diphtheria and tetanus toxoids and pertussis vaccine adsorbed (DTP): response to varying immunizing dosage and schedule.
    Barkin RM; Samuelson JS; Gotlin LP
    Dev Biol Stand; 1985; 61():297-307. PubMed ID: 2872117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acellular pertussis vaccination of 2-month-old infants in the United States.
    Pichichero ME; Francis AB; Blatter MM; Reisinger KS; Green JL; Marsocci SM; Disney FA
    Pediatrics; 1992 May; 89(5 Pt 1):882-7. PubMed ID: 1579399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of an acellular pertussis-component diphtheria-tetanus-pertussis (DTP) vaccine with a whole-cell pertussis-component DTP vaccine in 17- to 24-month-old children, with measurement of 69-kilodalton outer membrane protein antibody.
    Blumberg DA; Mink CM; Cherry JD; Reisinger KS; Blatter MM; Congeni BL; Dekker CL; Stout MG; Mezzatesta JR; Scott JV
    J Pediatr; 1990 Jul; 117(1 Pt 1):46-51. PubMed ID: 2196360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathophysiology of reactions associated with pertussis vaccine.
    Blumberg DA; Mink CM; Lewis K; Chatfield P; Leach C; Smith LP; Christenson PD; Guravitz L; Steinfeld MB; Marcy SM
    Dev Biol Stand; 1991; 73():289-95. PubMed ID: 1778321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of a Haemophilus influenzae type B polysaccharide-tetanus toxoid conjugate vaccine combined with diphtheria, tetanus and pertussis vaccines in Thai infants.
    Chotpitayasunondh T; Panpitpat C; Thisyakorn U; Furer E; Que JU; Hasler T; Cryz SJ
    Southeast Asian J Trop Med Public Health; 1997 Mar; 28(1):91-8. PubMed ID: 9322290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine.
    Gustafsson L; Hallander HO; Olin P; Reizenstein E; Storsaeter J
    N Engl J Med; 1996 Feb; 334(6):349-55. PubMed ID: 8538705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pertussis booster vaccination in HIV-infected children receiving highly active antiretroviral therapy.
    Abzug MJ; Song LY; Fenton T; Nachman SA; Levin MJ; Rosenblatt HM; Pelton SI; Borkowsky W; Edwards KM; Peters J;
    Pediatrics; 2007 Nov; 120(5):e1190-202. PubMed ID: 17938165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary immunization series for infants: comparison of two-component acellular and standard whole-cell pertussis vaccines combined with diphtheria-tetanus toxoids.
    Feldman S; Perry CS; Andrew M; Jones L; Moffitt JE; Lamb D; Meschievitz C
    South Med J; 1993 Mar; 86(3):269-75, 284. PubMed ID: 8451663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.